Literature DB >> 11208503

Repeated cyclosporine therapy of peripheral arthritis associated with ankylosing spondylitis.

P Géher1, B Gömör.   

Abstract

BACKGROUND: A case history of a patient with ankylosing spondylitis and peripheral arthritis unresponsive to the conventional drug therapy, but successfully controlled by the use of cyclosporin.
MATERIAL AND METHODS: In a 68 years old female patient with a 36 years history of typical ankylosing spondylitis a peripheral polyarthritis (hands, feet, wrists, and knees) developed. The patient did not suffer any other disease known to cause secondary spondylitis (psoriasis, inflammatory, bowel, disease). After the unsuccessful use of non-steroidal antiinflammatory drugs a combination therapy with cyclosporin (4 mg/kg/day) and azapropazone (300 mg t.i.d.) was introduced.
RESULTS: Clinical improvement was achieved after 6 months of combined therapy, the polyarthritis completely resolved after one year. Therefore cyclosporin was discontinued. After one year the polyarthritis reappeared therefore the cyclosporin therapy was reinstituted with success.
CONCLUSION: Cyclosporin has proved consistently effective in our case to control the peripheral arthritis associated with ankylosing spondylitis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11208503

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN: 1234-1010


  3 in total

Review 1.  Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis.

Authors:  J Zochling; D van der Heijde; M Dougados; J Braun
Journal:  Ann Rheum Dis       Date:  2005-08-26       Impact factor: 19.103

2.  Association of Genetic Variants in Pentraxin 3 Gene with Ankylosing Spondylitis.

Authors:  Xu Zhang; Wenyuan Ding
Journal:  Med Sci Monit       Date:  2016-08-18

Review 3.  Acquired pure red cell aplasia in a patient with ankylosing spondylitis- a case report and literature review.

Authors:  Xianfang Shao; Wei Wei; Yangzhi Zhao; Xinyue Liang; Qiuju Liu
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.